Shashikant Srivastava

Has grant

Associate Professor of Pulmonary Immunology

The University of Texas Health Science Center at Tyler

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Shashikant Srivastava is an Associate Professor of Pulmonary Immunology at The University of Texas Health Science Center at Tyler, USA. His research focuses on pharmacokinetics and pharmacodynamics related to Mycobacterium tuberculosis and Mycobacterium abscessus, as well as antibiotic resistance mechanisms in Staphylococcus aureus. Recent publications include studies on drug repurposing for Buruli ulcer and therapeutic potentials for lung disease caused by various mycobacteria.

Recent Grants

Grant: Close

Reinforcing old warriors to treat Mycobacterium kansasii in shorter duration

Open Date: 2020-09-01

Close Date: 2023-08-31

Grant: Close

PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB

Open Date: 2019-09-01

Close Date: 2024-07-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Tania Thomas

Associate Professor

Virginia Commonwealth University Medical Center

UNITED STATES

View details

Jan-Willem Alffenaar

University of Sydney

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shashikant Srivastava

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus

Erratum for Singh et al., “Repurposing drugs to advance the treatment of Buruli ulcer”

Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease

Repurposing drugs to advance the treatment of Buruli ulcer

A mechanistic understanding of the effect of Staphylococcus aureus VraS histidine kinase single-point mutation on antibiotic resistance

Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis

Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model

Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation

Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model

Meropenem-vaborbactam restoration of first-line drugs’ efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”

Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections

Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria

Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection

An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant <i>Mycobacterium tuberculosis</i>.

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against <i>Mycobacterium tuberculosis</i>.

Collaborators (2)

Tania Thomas

Jan-Willem Alffenaar

Make your next move.